IMPACT OF DIABETES MELLITUS ON THE OUCOME OF HEART FAILURE PATIENTS WITH REDUCED EJECTION FRACTION | ||
| ALEXMED ePosters | ||
| Article 1, Volume 6, Issue 4, September 2024, Pages 53-54 | ||
| Document Type: Preliminary preprint short reports of original research | ||
| DOI: 10.21608/alexpo.2024.334235.1997 | ||
| Authors | ||
| Tarek Hussein Elzawawy1; Gehan Magdy Yousef1; Ahmed Mahmoud El Amrawy2; Amina Ibrahim Rezk El hakim* 1 | ||
| 1Department of Cardiology and Angiology, Faculty of Medicine, Alexandria University | ||
| 2Department of Cardiology and Angiology, Faculty of Medicine- Alexandria University | ||
| Abstract | ||
| Diabetes and heart failure are closely related, patients with diabetes have an increased risk of developing heart failure and those with heart failure are at higher risk for DM also antidiabetic medications increase the risk of mortality and hospitalisation for heart failure in patients with and without previous heart failure. When the two diseases are considered individually, heart failure has a much poorer prognosis than diabetes mellitus; so heart failure has to be a priority for treatment in patients coming with the two conditions, and the diabetic patient with heart failure should be managed by the heart failure team. prevalence of HF in diabetes mellitus is four-times higher than that of the general population, suggesting a pathogenetic role of diabetes in heart failure. This pathogenetic role is also suggested by the fact that patients with diabetes and without heart failure have an increased risk of developing heart failure compared with a matched population (29 versus 18 %, respectively). The EMPA-REG outcomes trial, empagliflozin reduced the composite outcome of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with diabetes and established cardiovascular disease. In the DECLARE-TIMI 58 trial, dapagliflozin reduced (HF) hospitalizations in patients with diabetes and established/at high risk of cardiovascular disease. A US health maintenance study demonstrated that every 1 % increase in baseline glycosylated hemoglobin level correlated with a 15 % increased risk of developing HF, poor glycemic control was associated with an increased risk of HF. | ||
| Keywords | ||
| IMPACT; DM; HF | ||
|
Supplementary Files
|
||
|
Statistics Article View: 3 |
||
